All Documents

Events

Events & Presentations

Investor Video

View Video

Press Releases

Dec 02, 2021
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib    read more...
Dec 02, 2021
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease    read more...
Dec 02, 2021
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021    read more...
Press Releases

Thank you for your interest in Beigene, Ltd ! You will receive an email shortly. Please confirm your email address by clicking the link inside.

Back to the form